A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Must have received: standard treatment

after failure or intolerance to standard treatment or for which no standard treatment is available

Cannot have received: antibody-drug conjugate with topoisomerase I inhibitor

Prior treatment with an ADC drug with a topoisomerase I inhibitor as a toxin

Cannot have received: antineoplastic therapy

Exception: within 4 weeks or 5 half-lives before the first dose

Use of antineoplastic therapy within 4 weeks or 5 half-lives before the first dose

Cannot have received: mitomycin (mitomycin)

Exception: within 6 weeks before the first dose

Mitomycin and nitrosoureas were administered within 6 weeks before the first dose

Cannot have received: nitrosoureas (nitrosoureas)

Exception: within 6 weeks before the first dose

Mitomycin and nitrosoureas were administered within 6 weeks before the first dose

Cannot have received: oral fluorouracil (oral fluorouracil)

Exception: within 2 weeks before the first dose

Oral fluorouracil or palliative radiotherapy within 2 weeks before the first dose

Cannot have received: palliative radiotherapy

Exception: within 2 weeks before the first dose

Oral fluorouracil or palliative radiotherapy within 2 weeks before the first dose

Cannot have received: immunomodulatory drug

Exception: within 14 days before the first dose of study drug (Cohort_B, Cohort_C only)

Cohort_B, Cohort_C, who had received an immunomodulatory drug within 14 days before the first dose of study drug